$CELZ
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

2017 Q1 Form 10-K Financial Statement

#000114420417007873 Filed on February 13, 2017

View on sec.gov

Income Statement

Concept 2017 Q1 2015 Q4 2015
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue $0.00
YoY Change
Gross Profit $0.00
YoY Change
Gross Profit Margin
Selling, General & Admin $180.0K $10.00K $20.83K
YoY Change 28.57% 4.15%
% of Gross Profit
Research & Development $59.83K $0.00
YoY Change 1271.01%
% of Gross Profit
Depreciation & Amortization $0.00
YoY Change
% of Gross Profit
Operating Expenses $240.8K $500.00 $20.83K
YoY Change 63.7% 4.15%
Operating Profit -$240.8K -$500.00
YoY Change 62.9%
Interest Expense $2.505K $0.00 -$9.930K
YoY Change -0.7%
% of Operating Profit
Other Income/Expense, Net -$2.505K
YoY Change
Pretax Income -$243.4K -$10.00K -$30.76K
YoY Change 62.23% 0.0% 2.53%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$243.4K -$500.00 -$30.76K
YoY Change 64.6% -95.0% 2.53%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$1.736K -$369.30 -$254.6K
COMMON SHARES
Basic Shares Outstanding 105.0M shares 18.11M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q1 2015 Q4 2015
SHORT-TERM ASSETS
Cash & Short-Term Investments $100.0K $0.00 $100.00
YoY Change
Cash & Equivalents $98.12K $100.00
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $98.12K $49.60K $49.60K
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $98.01K $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $98.12K $49.60K $49.60K
Total Long-Term Assets $98.01K $0.00 $0.00
Total Assets $196.1K $49.60K $49.60K
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $96.88K $0.00 $0.00
YoY Change 384.4% -100.0% -100.0%
Accrued Expenses $6.891K $0.00 $0.00
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $100.0K $0.00 $100.00
YoY Change -33.33% -100.0% -99.93%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $468.9K $100.00 $100.00
YoY Change 175.81% -99.93% -99.93%
LONG-TERM LIABILITIES
Long-Term Debt $30.00K $0.00 $0.00
YoY Change 50.0%
Other Long-Term Liabilities $0.00
YoY Change
Total Long-Term Liabilities $30.00K $0.00 $0.00
YoY Change 50.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $468.9K $100.00 $100.00
Total Long-Term Liabilities $30.00K $0.00 $0.00
Total Liabilities $495.8K $100.00 $100.00
YoY Change 160.95% -99.93% -99.93%
SHAREHOLDERS EQUITY
Retained Earnings -$1.010M -$500.00
YoY Change
Common Stock $710.2K $50.00K
YoY Change 610.25%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$300.0K $49.50K $49.50K
YoY Change
Total Liabilities & Shareholders Equity $196.1K $49.60K $49.60K
YoY Change

Cashflow Statement

Concept 2017 Q1 2015 Q4 2015
OPERATING ACTIVITIES
Net Income -$243.4K -$500.00 -$30.76K
YoY Change 64.6% -95.0% 2.53%
Depreciation, Depletion And Amortization $0.00
YoY Change
Cash From Operating Activities -$223.7K $0.00 -$14.64K
YoY Change 459.37% -100.0% -26.8%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $100.0K 0.000 13.90K
YoY Change 100.0% -100.0% -30.5%
NET CHANGE
Cash From Operating Activities -$223.7K 0.000 -14.64K
Cash From Investing Activities 0.000 0.000 0.000
Cash From Financing Activities $100.0K 0.000 13.90K
Net Change In Cash -$123.7K 0.000 -740.0
YoY Change -1337.49%
FREE CASH FLOW
Cash From Operating Activities -$223.7K $0.00 -$14.64K
Capital Expenditures $0.00
Free Cash Flow -$223.7K
YoY Change 459.37%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
49500 USD
CY2016Q4 us-gaap Cash
Cash
221868 USD
CY2016Q4 us-gaap Assets
Assets
322512 USD
CY2015Q4 us-gaap Assets
Assets
49600 USD
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
66385 USD
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
0 USD
CY2016Q4 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
100000 USD
CY2015Q4 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
0 USD
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4879 USD
CY2015Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
0 USD
CY2016Q4 us-gaap Management Fee Payable
ManagementFeePayable
280000 USD
CY2015Q4 us-gaap Management Fee Payable
ManagementFeePayable
0 USD
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
105014 USD
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
32010 USD
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
503767 USD
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
17990 USD
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-766572 USD
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-500 USD
CY2016Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-157791 USD
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
322512 USD
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
49600 USD
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
453864 USD
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
100 USD
CY2016Q4 us-gaap Liabilities
Liabilities
480303 USD
CY2015Q4 us-gaap Cash
Cash
100 USD
CY2016Q4 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
0 USD
CY2015Q4 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
49500 USD
CY2016 us-gaap Operating Expenses
OperatingExpenses
759674 USD
CY2015Q4 us-gaap Revenues
Revenues
0 USD
CY2015Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
0 USD
CY2016Q4 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
25000 USD
CY2015Q4 us-gaap Liabilities
Liabilities
100 USD
CY2015Q4 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
0 USD
CY2016Q4 us-gaap Assets Current
AssetsCurrent
221868 USD
CY2015Q4 us-gaap Assets Current
AssetsCurrent
49600 USD
CY2016Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
2600 USD
CY2015Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
100 USD
CY2016Q4 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
1439 USD
CY2015Q4 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
0 USD
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2016 us-gaap Revenues
Revenues
0 USD
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
85334 USD
CY2016 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
664984 USD
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
-766072 USD
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-766072 USD
CY2016 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
94006533 shares
CY2016 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
CY2016 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
9356 USD
CY2015Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
500 USD
CY2015Q4 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0 USD
CY2015Q4 us-gaap Operating Expenses
OperatingExpenses
500 USD
CY2015Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-500 USD
CY2015Q4 us-gaap Net Income Loss
NetIncomeLoss
-500 USD
CY2015Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
32010000 shares
CY2015Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.00
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
2565 USD
CY2016 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
22601 USD
CY2016 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
6318 USD
CY2016 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
280000 USD
CY2016 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-445232 USD
CY2016 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
10000 USD
CY2016 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-10000 USD
CY2016 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
125000 USD
CY2016 celz Proceeds From Subscription Receivable
ProceedsFromSubscriptionReceivable
49500 USD
CY2016 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
500000 USD
CY2016 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
2500 USD
CY2016 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
677000 USD
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
221768 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
100 USD
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
221868 USD
CY2016 us-gaap Interest Paid
InterestPaid
0 USD
CY2016 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 USD
CY2015Q4 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
0 USD
CY2015Q4 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
0 USD
CY2015Q4 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
100 USD
CY2015Q4 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-400 USD
CY2015Q4 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
0 USD
CY2015Q4 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0 USD
CY2015Q4 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
500 USD
CY2015Q4 us-gaap Interest Paid
InterestPaid
0 USD
CY2015Q4 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 USD
CY2016 us-gaap Proceeds From Contributed Capital
ProceedsFromContributedCapital
0 USD
CY2015Q4 us-gaap Proceeds From Contributed Capital
ProceedsFromContributedCapital
500 USD
CY2015Q4 celz Proceeds From Subscription Receivable
ProceedsFromSubscriptionReceivable
0 USD
CY2016Q4 celz Working Capital Deficit
WorkingCapitalDeficit
231996 USD
CY2016Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
33493 USD
CY2016 celz Employee Service Sharebased Compensation Nonvested Awards Expiration Period
EmployeeServiceSharebasedCompensationNonvestedAwardsExpirationPeriod
2021
CY2016 dei Document Type
DocumentType
10-K
CY2016 dei Amendment Flag
AmendmentFlag
false
CY2016 dei Document Period End Date
DocumentPeriodEndDate
2016-12-31
CY2016 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
CY2016 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2016 dei Entity Registrant Name
EntityRegistrantName
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
CY2016 dei Entity Central Index Key
EntityCentralIndexKey
0001187953
CY2016 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2016 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2016 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2016 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2016 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2016Q2 dei Entity Public Float
EntityPublicFloat
0 USD
CY2016 dei Trading Symbol
TradingSymbol
CELZ
CY2017Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
105013750 shares
CY2016Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
100644 USD
CY2015Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
0 USD
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
600000000 shares
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
600000000 shares
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
105013750 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
105013750 shares
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
32010000 shares
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32010000 shares
CY2016 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
6398 USD
CY2015Q4 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
0 USD
CY2015Q4 us-gaap Share Based Compensation
ShareBasedCompensation
0 USD
CY2015Q4 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
0 USD
CY2015Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
CY2015Q4 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
0 USD
CY2016 us-gaap Use Of Estimates
UseOfEstimates
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><i><font style="FONT-SIZE: 10pt">Use of Estimates</font></i></b><i><font style="FONT-SIZE: 10pt">&#160;-&#160;</font></i> <font style="FONT-SIZE: 10pt">The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and the reported amounts of revenues and expenses during the reporting period. &#160;Actual results could differ from those estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2016 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><i><font style="FONT-SIZE: 10pt">Concentration Risks -</font></i></b><font style="FONT-SIZE: 10pt">&#160;The Federal Deposit Insurance Corporation insures cash deposits in most general bank accounts for up to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">250,000</font> per institution. &#160;The Company maintains its cash balances at one financial institution and at times the cash balances may exceed this amount.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2016Q4 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 USD
CY2016 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
445232 USD
CY2016Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
11176 USD
CY2016Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
11176 USD
CY2016Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
11176 USD
CY2016Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
11176 USD
CY2016Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
11176 USD
CY2016Q4 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
44764 USD
CY2016 us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
420000 USD
CY2016Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
557000 USD
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
0 USD
CY2015Q4 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
50000 USD
CY2016 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
-199179 USD
CY2015 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
0 USD
CY2016 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
-61286 USD
CY2015 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
0 USD
CY2016 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-260464 USD
CY2015 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
0 USD
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
49500 USD
CY2016 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
470000 USD
CY2016 celz Stock Issued During Period To Related Party Value New Issues
StockIssuedDuringPeriodToRelatedPartyValueNewIssues
30000 USD
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
189064 USD
CY2015Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
0 USD
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
71400 USD
CY2015Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
0 USD
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
260464 USD
CY2016Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 USD
CY2015Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 USD
CY2016 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
-44784 USD
CY2016 us-gaap Stock Redeemed Or Called During Period Value
StockRedeemedOrCalledDuringPeriodValue
0 USD
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2565 USD
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
-157791 USD
CY2016 us-gaap Liabilities Assumed1
LiabilitiesAssumed1
43784 USD
CY2015Q4 us-gaap Liabilities Assumed1
LiabilitiesAssumed1
0 USD
CY2016 celz Fair Value Of Warrants Issued In Private Placement
FairValueOfWarrantsIssuedInPrivatePlacement
32530 USD
CY2015Q4 celz Fair Value Of Warrants Issued In Private Placement
FairValueOfWarrantsIssuedInPrivatePlacement
0 USD
CY2016 celz Class Of Warrant Or Right Conversion Ratio
ClassOfWarrantOrRightConversionRatio
one warrant to purchase another share of common stock at $0.10 per share for each ten shares purchased in the offering.

Files In Submission

Name View Source Status
0001144204-17-007873-index-headers.html Edgar Link pending
0001144204-17-007873-index.html Edgar Link pending
0001144204-17-007873.txt Edgar Link pending
0001144204-17-007873-xbrl.zip Edgar Link pending
celz-20161231.xml Edgar Link completed
celz-20161231.xsd Edgar Link pending
celz-20161231_cal.xml Edgar Link unprocessable
celz-20161231_def.xml Edgar Link unprocessable
celz-20161231_lab.xml Edgar Link unprocessable
celz-20161231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v458672_10k.htm Edgar Link pending
v458672_ex31-1.htm Edgar Link pending
v458672_ex31-2.htm Edgar Link pending
v458672_ex32-1.htm Edgar Link pending
v458672_ex32-2.htm Edgar Link pending